Lymphoma Clinical Trials

Showing 881-900 of 3,379 trials

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

NCT05209620

This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.

Central Nervous System Lymphoma

Henan Cancer Hospital30 participantsStarted Dec 2021

Zhengzhou, Henan, China

Active Not RecruitingPhase 1/2

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

NCT02797470

This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.

HIV InfectionMature T-Cell and NK-Cell Non-Hodgkin LymphomaPlasmablastic Lymphoma+8 more

AIDS Malignancy Consortium11 participantsStarted Jun 2016

La Jolla, California, United States • Sacramento, California, United States • San Francisco, California, United States +1 more locations

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Related Searches

A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Improved Early Diagnosis in Female Pelvic Cancer With OC Detect

Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma

Chemotherapy Induced Peripheral Neuropathy (CIPN) and Lymphoma Longitudinal Follow-up and Prognostic Factors

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

AGMT Austrian Lymphoma Registry

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma